Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 12/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.47 |
| ▸ | NPY1R | P25929 | 4/20 | 0.47 |
| ▸ | NPY4R | P50391 | 4/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.45 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715782 | 0.88 | OPRM1 (0.51) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20715847 | 0.88 | OPRM1 (0.51) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20715790 | 0.84 | OPRM1 (0.47) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL24340659 | 0.82 | NPY5R (0.46) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20715581 | 0.80 | OPRM1 (0.51) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL24325323 | 0.77 | GRIA1 (0.48) | — | |
| SCHEMBL24341151 | 0.76 | OPRM1 (0.46) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL24324975 | 0.76 | NPY4R (0.45) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL19234873 | 0.76 | OPRM1 (0.48) | NPBWR1NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20715781 | 0.76 | OPRM1 (0.45) | NPBWR1NPY5RNPY1RNPY4RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | NPBWR1 60/4885NPY5R 24/4885NPY1R 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.